Precision oncology’s translation gap—Can molecular tumor boards bridge it?
Precision oncology is revolutionizing cancer care, but isn't reaching enough patients. Molecular tumor boards (MTBs) translate complex genomic data to more effectively inform personalized care, and a new meta-analysis shows they boost clinical outcomes. But how can we feasibly and equitably expand the use of MTBs?
Authors
- Jill Kolesar (ORCID: https://orcid.org/0000-0003-1802-6439)
- Margaret M. Byrne (ORCID: https://orcid.org/0000-0003-1007-9288)
Institutions
- University of Iowa (US)
Publication Details
- Journal
- PLoS Medicine
- Published
- 2026-06-30
- DOI
- https://doi.org/10.1371/journal.pmed.1005165
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 0.00